• Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=15378398).
  

PubMed=15378398; DOI=10.1007/s10038-004-0191-y
Misawa A., Hosoi H., Imoto I., Iehara T., Sugimoto T., Inazawa J.
Translocation (1;22)(p36;q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor.
J. Hum. Genet. 49:586-589(2004)

PubMed=18281554; DOI=10.1158/1078-0432.CCR-07-1661
Katsumi Y., Kuwahara Y., Tamura S., Kikuchi K., Otabe O., Tsuchiya K., Iehara T., Kuroda H., Hosoi H., Sugimoto T.
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Clin. Cancer Res. 14:1192-1199(2008)

PubMed=21871868; DOI=10.1016/j.bbrc.2011.08.047; PMCID=PMC3214763
Katsumi Y., Iehara T., Miyachi M., Yagyu S., Tsubai-Shimizu S., Kikuchi K., Tamura S., Kuwahara Y., Tsuchiya K., Kuroda H., Sugimoto T., Houghton P.J., Hosoi H.
Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.
Biochem. Biophys. Res. Commun. 413:62-68(2011)

CLPUB00599
Sugimoto T., Kuroda H., Kuwahara Y., Katsumi Y., Misawa A., Moritake H., Hosoi H.
Cellular and molecular characteristics of established childhood soft-tissue sarcoma cell lines.
J. Cancer Res. Therap. Oncol. 7:202.1-202.12(2019)